Spinal muscular atrophy (SMA) type I (Werdnig-Hoffmann disease)

Area of Science:

• Pediatrics
• Neurology
• Genetics

Background:

• Spinal muscular atrophy type I (Werdnig-Hoffmann disease) is the most severe form, presenting before 6 months with global hypotonia and absent reflexes.
• Affected infants exhibit normal cognitive development and expressive gaze despite severe motor impairment and potential bulbar and respiratory involvement.
• Type I SMA is subclassified into IA, IB, and IC based on symptom onset and severity, including head control and bulbar function.

Purpose of the Study:

• To describe the clinical characteristics and subtypes of Spinal Muscular Atrophy Type I.
• To highlight the impact of recent innovative therapies on the disease's natural course.
• To emphasize the need for further research into the long-term evolution of infants treated with novel therapies.

Main Methods:

• Review of clinical manifestations and diagnostic criteria for Spinal Muscular Atrophy Type I.
• Classification of Type I SMA into subtypes IA, IB, and IC based on clinical presentation.
• Discussion of the evolving therapeutic landscape and its implications.

Main Results:

• Spinal Muscular Atrophy Type I presents with severe hypotonia, absent reflexes, and potential respiratory and bulbar dysfunction.
• Subtypes IA, IB, and IC delineate disease severity and onset, impacting prognosis.
• Innovative therapies are altering the disease's natural progression, but long-term data is limited.

Conclusions:

• Spinal Muscular Atrophy Type I is a severe neuromuscular disorder with distinct subtypes.
• Emerging therapies offer hope but necessitate ongoing evaluation of long-term efficacy and safety.
• Further research is crucial to understand the long-term impact of new treatments on infants with SMA Type I.